Navigation Links
For Treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabThera's Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
Date:8/30/2010

BURLINGTON, Mass., Aug. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.

The new European Physician & Payer Forum report entitled Will Emerging MAbs Threaten MabThera's Domination of the Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Markets in Europe? Clinician and Payer Perspectives finds that sales of MabThera, which was first marketed more than a decade ago, continue to dwarf those of more recently launched monoclonal antibodies (MAbs) such as Genzyme's MabCampath and Bayer's Zevalin. When asked what safety/toxicity improvements over MabThera would carry the most weight in convincing prescribers to switch from MabThera to a novel MAb, the largest group of surveyed clinicians in France, Germany, Italy, Spain and the United Kingdom (EU5) cite concern about the rate of infections, although many are satisfied with the safety of MabThera.

"Thirty seven percent of surveyed European hematologist-oncologists say that an improvement in the rate of infections would carry the most weight, while 20 percent of surveyed clinicians cite concern about the rate of neutropenia," said Decision Resources Analyst Andrew Merron, Ph.D. "However, more than one-quarter of surveyed European hematologist-oncologists say that all side effects associated with MabThera are manageable."

The report also finds that emerging MAbs will not only face competition from MabThera in the EU5 markets but also from biosimilar rituximab. In the United Kingdom, interviewed payers expect that biosimilars will be
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Seeger Weiss LLP is reporting that on ... warning letter to C.R. Bard, the manufacturer of Inferior ... to correct violations the agency found at two of Bard,s ... the FDA cited them during Inspectional Observations that occurred on ... Tempe, AZ , location and on October 6, ...
(Date:7/31/2015)... , July 31, 2015 The Physician-Patient ... release on July 28, 2015, "Surviving Your Hospital ... Fundraising for Patient Safety." A sentence ... should read: "PPAHS is a member ... on Opioids. For more information on the National Coalition ...
(Date:7/31/2015)... -- Quietly, sedately, Morocco,s pharmaceutical sector is ... industry is strong, with a well-developed base of local ... One place where the quality of Moroccan ... has quietly become the second largest African exporter of ... Indeed, Moroccan pharma companies have been making inroads as ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3
... , LYNBROOK, N.Y., Nov. 24 BioSpecifics Technologies Corp. (Nasdaq: ... collagenase-based products, today announced that BioSpecifics, President, Tom Wegman, will ... Conference on Tuesday, December 1, 2009, at 3:30pm ET at ... A live webcast of the presentation can be accessed under ...
... , , CHICAGO, Nov. 23 Two ... introducing a new era in women,s breast imaging, coupling the ... with the ability to have the full range of digital ... leaves the office. Drs. Ahmed Farag and Joan Werber ...
Cached Medicine Technology:Noted Diagnostic Radiologists Joan Werber, D.O., Ahmed Farag, M.D., C.M., Join Forces to Create Diagnostic Imaging Specialists of Chicago 2
(Date:8/2/2015)... ... 2015 , ... A new Phase I research study is looking at a ... by Kenneth G. Lucas, M.D. , chief of the division of pediatric hematology/oncology ... Kosair Children’s Hospital and in the UofL Department of Pediatrics . ...
(Date:8/2/2015)... ... , ... For many “would be” entrepreneurs, starting a new business can prove to be ... start a business.” Neither needs be a major obstacle. , The U.S. has always ... business and be successful. The risks of starting a business can be high but the ...
(Date:8/2/2015)... Orion, Clarkston, Metamora Michigan (PRWEB) , ... ... ... Pelvic Organ Prolapse (POP) results when the supportive muscles and connective tissues ... damaged. Causes of this weakness and damage include straining, heavy lifting, obesity, ...
(Date:8/2/2015)... ... , ... Molecular biologists in New South Wales say a protein linked to ... posted an article on the new research. Click here to read it now. ... in tissue samples from 42 patients with peritoneal mesothelioma and found a direct correlation ...
(Date:8/1/2015)... ... August 02, 2015 , ... AlignLife Office ... help the continuity of care for patients at this natural health care center in ... Clinic Director Mary Heal said. "Heather's role is vital to our approach because we ...
Breaking Medicine News(10 mins):Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:New Patient Advocate Enhances Natural Health Care 2
... Cell-Based ... Melanoma Therapy, BOTHELL, Wash., ... developer and marketer of,proprietary hypothermic storage and cryopreservation media products for,cells, ... products in the cellular therapy and cord blood banking,market segments., ...
... Michelle Reesman, RN, Executive,Director, Passport Health Colorado, says far ... adventurous types, leave,home without taking the basic steps she ... preparation into their health as they do into their,destination ... 1) Get advice from a travel health ...
... LENEXA, Kan., Mar. 26 Mediware Information,Systems (Nasdaq: ... systems for,blood and medication management, has announced its ... hospital,blood banks and LifeTrak(R) software for blood centers, ... standards being required in the,United States., With ...
... for Voters on Health Care and,Social Security, ... said the most recent Medicare trustees, report calls ... issues.,According to the program,s trustees, Medicare,s Hospital Insurance ... Medicare must,rely also on interest accrued on trust ...
... 26 Spheris, a leading global,outsource provider of clinical ... and twelve months ended December 31, 2007., Financial ... fourth quarter of 2007 were $48.6 million compared,with $51.4 ... million decrease,in net revenues during the fourth quarter of ...
... a company,developing breakthrough molecular imaging agents for ... it has entered into a licensing,agreement with ... and,commercialization of agents for diagnosis and treatment ... were co-developed by,FluoroPharma and MGH scientists, target ...
Cached Medicine News:Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 2Health News:BioLife Solutions Expands Presence in Cell Therapy and Cord Blood Banking Market Segments 3Health News:The Top Ten Health Tips for International Travel 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 2Health News:ISBT 128 Labeling Implementation Date Looms for Blood Centers 3Health News:Medicare Trustees' Report Highlights Need for Reform 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 3Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 4Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 5Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 6Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 7Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 8Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 9Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 10Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 11Health News:FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD) 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: